Reversing or preventing premature vascular senescence

Details Reversing or preventing premature vascular senescence Reversing or preventing premature vascular senescence

2005-11-22

2005-11-22

Jones, Dwayne (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C514S564000

Reexamination Certificate

active

06967219

ABSTRACT:
Premature vascular senescence is reversed or prevented in tissue or cells by contacting the tissue or cells with a hydroxyguanidine. This finds application in treatment of patients with a disorder associated with elevated levels of advanced glycation end products in blood or tissue, e.g., patients with end stage renal disease or poorly controlled diabetes, and in contacting vascular tissue or cells ex vivo to prevent occurrence of premature senescence.

REFERENCES:
patent: 5140048 (1992-08-01), Ulrich et al.
patent: 5478946 (1995-12-01), Murad et al.
patent: 6784178 (2004-08-01), Gross et al.
patent: 2003/0086916 (2003-05-01), Goligorsky et al.
patent: 2004/0024060 (2004-02-01), Lundstedt et al.
Dambrova et al., “N-hydroxyguanidine compound 1-(3,4-dimethoxy-2-chlorobenzylideneamino)-3-hydroxguanidine inhibits the xanthine oxidase mediated generation of superoxide radical”, Abstract , Archives of Biochem. and Biophysics, May 1, 2000, 377(1), 101-8.
WEBSTER'S II, New Riverside University Dictionary, p. 933, 1988.

Affiliated with

Also associated with

Rating

Reversing or preventing premature vascular senescence does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reversing or preventing premature vascular senescence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reversing or preventing premature vascular senescence will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3464362